One Bench at a Time

Logicink announces first product to market: Logicink UV

 

Logicink San Francisco Team (left to right): Kari Workman, Claire LeMaitre, Steven Wrobel, Julie Cushen, Carlos Olguin

On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage.

The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can cause (1) severe diseases such as skin cancer and (2) the premature aging of the skin (photoaging). LogicInk UV is not powered by electronics. Instead its user interface is programmed with chemistry, alerting users when they have reached a safe daily UV limit determined by medical research on minimal erythemal dose (MED). MED identifies the least amount of UV exposure needed for each skin tone to get a noticeable sunburn.

LogicInk has raised $1M in a pre-seed round from Mission Bay Capital; Peter Thiel’s Breakout Labs, Berkeley Catalyst Fund; Antoine Blondeau, the CEO of Sentient.ai; and others. LogicInk is currently raising a seed round.

Logicink is asking anyone interested in the upcoming beta program to sign up now at http://logic.ink to stay informed about when and how to try LogicInk UV.

qb3at953 News

Upcoming Event

  • Capitalizing on New Trends of Chinese Investments in the U.S. and Navigating Legal Issues for Startups in China

    12:30-13:30
    01/23/2018
    Karen Wong, PhD, Partner Wilson Sonsini Goodrich & Rosati RSVP The rapid growth of the healthcare market in China is fueling many Chinese funds and pharmaceutical companies to invest in healthcare companies in the US and to attract talent to set up companies in China. This presents an unprecedented cross-border environment and new business opportunities for Bay Area entrepreneurs. Please join us for a lively and hands-on discussion with Dr. Karen Wong, a partner of Wilson Sonsini Goodrich & Rosati, to learn about real-life stories, opportunities, and pitfalls in setting up startups with planned growth or commercialization in China. Karen will cover the topics of US-China cross-border deal structures, technology transfer and licensing, fundraising and term-sheet negotiation, and patent filing strategies for both the US and China markets. Dr. Karen Wong has a wealth of experience in life sciences patent preparation and prosecution, technology transfer and licenses, and due-diligence studies in connection with VC financing, M&A, and public offering. Dr. Karen Wong has served as IP counsel to many venture-backed companies in the US and in China, and has worked on numerous major cross-border transactions, strategic alliance transactions, acquisitions, spin-outs, and IPOs. Karen is fluent in Mandarin, Cantonese, and Sichuan dialect.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter